Inclisiran, a GalNAc-modified siRNA targeting PCSK9, has consistently shown both effectiveness and a positive safety profile, leading to its approval for treating FH and atherosclerotic CVD.274. Here, PCSK9 is linked to familial hyperaldosteronism.